ArticleScience advances2020
Aneuploidy and a deregulated DNA damage response suggest haploinsufficiency in breast tissues of
Open access · goldAbstract read
In one paragraph
Article in Science advances, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 32 papers, 1 of them a synthesis that pooled it.
0numbers the graph read from it
0cells of the map it votes in
32citing papers in PubMed, 1 pooled it
4.3field-weighted citation impact, top 6% of its field
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
32 citing papers in PubMed, 1 synthesis or guideline pooled it, 43 citations in OpenAlex.
- DDX17 is required for efficient DSB repair at DNA:RNA hybrid deficient loci.Nucleic acids research · 2022Pooled it
- Gastric Epithelium from BRCA1 and BRCA2 Carriers Harbors Increased Double-Stranded DNA Damage and Enhanced Growth Potential.Molecular cancer research : MCR · 2026Article
- Rethinking ovarian cancer III: the past decade and future directions.Nature reviews. Cancer · 2026Review
- A recurrent pathogenic BRCA2 truncating variant reveals a role for BRCA2-PCAF complex in modulating NF-κB-driven transcription.Nature communications · 2025Article
- BRCA2 deficiency and replication stress drive APOBEC3-Mediated genomic instability.Nature communications · 2025Article
- Gastric epithelium frombioRxiv : the preprint server for biology · 2025Article
- Healthy BRCA1/2 mutation carriers exhibit a pre-CAF signature and altered epithelial marker expression in breast tissue.Scientific reports · 2025Article
- Detecting likely germline variants during tumor-based molecular profiling.The Journal of clinical investigation · 2025Review
- Death-ision: the link between cellular resilience and cancer resistance to treatments.Molecular cancer · 2025Review
- Epigenomic disorder and partial EMT impair luminal progenitor integrity in Brca1-associated breast tumorigenesis.Molecular cancer · 2025Article
- BRCA1 and BRCA2: from cancer susceptibility to synthetic lethality.Genes & development · 2025Review
- Cells-of-Origin of Breast Cancer and Intertumoral Heterogeneity.Advances in experimental medicine and biology · 2025Review
- Article
- PALB2-mutated human mammary cells display a broad spectrum of morphological and functional abnormalities induced by increased TGFβ signaling.Cellular and molecular life sciences : CMLS · 2024Article
- BRCA2 promotes genomic integrity and therapy resistance primarily through its role in homology-directed repair.Molecular cell · 2024Article
- Spatial Transcriptomics Suggests That Alterations Occur in the Preneoplastic Breast Microenvironment of BRCA1/2 Mutation Carriers.Molecular cancer research : MCR · 2024Article
- Signaling Pathway Alterations Driven by BRCA1 and BRCA2 Germline Mutations are Sufficient to Initiate Breast Tumorigenesis by the PIK3CAH1047R Oncogene.Cancer research communications · 2024Article
- Cell origin of BRCA2-mutant breast cancer.Nature cell biology · 2024Article
- Identification of aberrant luminal progenitors and mTORC1 as a potential breast cancer prevention target in BRCA2 mutation carriers.Nature cell biology · 2024Article
- Contralateral breast cancer risk with radiation therapy in BRCA mutation carriers: what do we tell patients?Journal of the National Cancer Institute · 2023Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
16 authors at 5 institutions in 1 country.
Mihriban Karaayvaz-YildirimCenter for Cancer Research, Massachusetts General Hospital and Harvard Medical School, Boston, MA 02114, USA.ORCID 0000-0002-6264-2477
Rebecca E SilbermanKoch Institute for Integrative Cancer Research, Department of Biology, Howard Hughes Medical Institute, Massachusetts Institute of Technology, Cambridge, MA 02139, USA.ORCID 0000-0002-5655-2176
Adam LangenbucherCenter for Cancer Research, Massachusetts General Hospital and Harvard Medical School, Boston, MA 02114, USA.
Srinivas Vinod SaladiCenter for Cancer Research, Massachusetts General Hospital and Harvard Medical School, Boston, MA 02114, USA.ORCID 0000-0001-8147-4379
Kenneth N RossCenter for Cancer Research, Massachusetts General Hospital and Harvard Medical School, Boston, MA 02114, USA.ORCID 0000-0002-1723-8520
Elena ZarcaroCenter for Cancer Research, Massachusetts General Hospital and Harvard Medical School, Boston, MA 02114, USA.
Andrea DesmondCenter for Cancer Research, Massachusetts General Hospital and Harvard Medical School, Boston, MA 02114, USA.
Murat YildirimPicower Institute for Learning and Memory, Massachusetts Institute of Technology, Cambridge, MA 02139, USA.ORCID 0000-0003-0853-2557
Varunika VivekanandanCenter for Cancer Research, Massachusetts General Hospital and Harvard Medical School, Boston, MA 02114, USA.
Hiranmayi RavichandranDepartment of Pathology, Massachusetts General Hospital and Harvard Medical School, Boston, MA 02114, USA.
Ravindra MylavagnanamDepartment of Pathology, Massachusetts General Hospital and Harvard Medical School, Boston, MA 02114, USA.ORCID 0000-0001-5336-6557
Michelle C SpechtDepartment of Surgery, Massachusetts General Hospital, Boston, MA 02114, USA.
Sridhar RamaswamyCenter for Cancer Research, Massachusetts General Hospital and Harvard Medical School, Boston, MA 02114, USA.
Michael LawrenceCenter for Cancer Research, Massachusetts General Hospital and Harvard Medical School, Boston, MA 02114, USA.ORCID 0000-0002-1307-459X
Angelika AmonKoch Institute for Integrative Cancer Research, Department of Biology, Howard Hughes Medical Institute, Massachusetts Institute of Technology, Cambridge, MA 02139, USA.ORCID 0000-0001-9837-0314
Leif W EllisenCenter for Cancer Research, Massachusetts General Hospital and Harvard Medical School, Boston, MA 02114, USA.ORCID 0000-0003-0444-7910
Harvard University · USBroad Institute · USHoward Hughes Medical Institute · USMassachusetts General Hospital · USMassachusetts Institute of Technology · US
Funding
PRE-DOCTORAL TRAINING IN THE BIOLOGICAL SCIENCEST32GM007287 · NIGMS · MASSACHUSETTS INSTITUTE OF TECHNOLOGY · PI BELL, STEPHEN P., KEATING, AMY E · 1985 to 2019
$40.8MDeveloping next generation multiphoton systems to reveal cortico-thalamic interactions underlying short-term memory in behaving miceK99EB027706 · NIBIB · MASSACHUSETTS INSTITUTE OF TECHNOLOGY · PI YILDIRIM, MURAT · 2020 to 2021
$184kNIBIB NIH HHS K99 EB027706NIGMS NIH HHS T32 GM007287
Abstract
Women harboring heterozygous germline mutations of
Indexed as
Genetic Predisposition to DiseaseAdultAneuploidyBRCA2 ProteinBreast NeoplasmsCell Line, TumorDNA Copy Number VariationsDNA DamageFemaleGerm-Line MutationHaploinsufficiencyHeterozygoteHumansMiddle AgedSingle-Cell AnalysisBRCA2 ProteinBRCA2 protein, human
Identifiers
What OpenQuestion holds
Textmetadata
LicenceCC BY-NC
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.